ValiRx plc ( (GB:VAL) ) has provided an update.
ValiRx Plc, a life science company specializing in early-stage cancer therapeutics and women’s health, announced the conclusion of an evaluation project with Imperial College London. Despite initial promising results, ValiRx decided not to pursue further development of the Dual Kinase series drug candidates and will return the project to the university. This decision marks the termination of their collaboration agreement, with Imperial College resuming responsibility for maintaining the intellectual property. The project’s conclusion suggests a shift in the company’s strategic focus, while maintaining a collaborative relationship with the university for potential future projects.
More about ValiRx plc
ValiRx is a life science company focused on early-stage cancer therapeutics and women’s health. The company accelerates the translation of innovative science into impactful medicines to improve patient lives, connecting scientific, technical, and commercial disciplines to streamline drug development. Listed on the AIM Market of the London Stock Exchange, ValiRx’s strategy involves selecting, incubating, and developing promising drug candidates through pre-clinical studies, with the aim of outlicensing or partnering them for further clinical development and commercialization.
YTD Price Performance: -19.35%
Average Trading Volume: 10,473,772
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £2.34M
For detailed information about VAL stock, go to TipRanks’ Stock Analysis page.